AIM

AIM ImmunoTech Inc.

0.42 USD
+0.04 (+11.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AIM ImmunoTech Inc. stock is up 0.93% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 39.29% of the previous 27 February’s closed higher than January.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS) It is also developing Ampligen for the. treatment of renal cell carcinoma, malignant melanoma,. non-small cell lung, ovarian, breast,. breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis